A Phase 1, Multicenter, Open-Label Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of TAB006, As Monotherapy And In Combination With Toripalimab, In Patients With Previously Treated, Advanced Malignancies Read more
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT) Read more
Phase I Study Dose Finding Study To Evaluate Safety, Reactogenicity And Immunogenicity Of CV09040102 RAS G12D Mrna Vaccine In HLA- Selected Patients With Pancreatic Cancer Or Colorectal Cancer Harboring The RAS G12D Mutation Read more
Dose Escalation In Patients With Advanced Solid Tumors, And Expansion In Selected Indications Read more
An Open-Label, Multicenter, Dose-Escalation, Phase I Study To Evaluate Safety, Pharmacokinetics, And Preliminary Anti-Tumor Activity Of Ro7444973 In Participants With Advanced And/Or Metastatic Mage A4-Positive, Solid Tumors. Read more
A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies Read more
A Phase 1, First-in-Human, Open- Label, Dose Escalation and Cohort Expansion Study of MGD019, a Bispecific DART® Protein Binding PD-1 and CTLA-4 in Patients with Unresectable or Metastatic Neoplasms? (the ?Study?). Read more
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study Of Pembrolizumab (MK-3475) In Combination With Concurrent Chemoradiation Therapy Followed By Pembrolizumab With Or Without Olaparib (MK-7339), Compared To Concurrent Chemoradiation Therapy Alone In Participants With Actively Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) Read more
